Protalix BioTherapeutics
PLX
45 hedge funds and large institutions have $141M invested in Protalix BioTherapeutics in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 10 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
0.11% more ownership
Funds ownership: 3.75% → 3.87% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 47 → 45 (-2)
12% less capital invested
Capital invested by funds: $159M → $141M (-$18.4M)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
98% less call options, than puts
Call options by funds: $40K | Put options by funds: $2.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.53M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$1.6M |
| 3 |
BlackRock
New York
|
+$1.55M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$884K |
| 5 |
First Eagle Investment Management
New York
|
+$842K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$1.55M |
| 2 |
SAM
Silverback Asset Management
Chapel Hill,
North Carolina
|
-$1.23M |
| 3 |
U
UBS
Zurich,
Switzerland
|
-$991K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$851K |
| 5 |
D.E. Shaw & Co
New York
|
-$600K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Two Sigma Advisers
New York
| – | -$50K | -1,120 | Closed |
|
|
ACM
52
Aviance Capital Management
Sarasota,
Florida
| – | -$1K | -21 | Closed |
|
PLX Hedge Fund Activity: Q4 2013 in Review
45 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2013, worth a combined $141M — down 12% from $159M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of PLX and 8 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 14 added.
The largest buyer was Great Point Partners, adding an estimated $2.53M. The largest seller was BlackRock Advisors, cutting an estimated $1.55M.
- 45 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2013, down from 47 in Q3 2013.
- Funds reported $141M of Protalix BioTherapeutics stock for Q4 2013, down 12% quarter-over-quarter.
- 8 funds opened new Protalix BioTherapeutics positions in Q4 2013 and 10 closed out, a net change of -2 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2013 was Great Point Partners, an estimated $2.53M added.
- The largest Protalix BioTherapeutics seller in Q4 2013 was BlackRock Advisors, an estimated $1.55M sold.
Based on aggregated 13F filings for Q4 2013.